60 related articles for article (PubMed ID: 11437473)
21. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
Christopher R; Covington P; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
Clin Ther; 2008 Mar; 30(3):513-27. PubMed ID: 18405789
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
23. Does growth hormone allow more efficient nitrogen sparing in postoperative patients requiring parenteral nutrition? A double-blind, placebo-controlled randomised trial.
Sevette A; Smith RC; Aslani A; Kee AJ; Hansen R; Barratt SM; Baxter RC
Clin Nutr; 2005 Dec; 24(6):943-55. PubMed ID: 16083996
[TBL] [Abstract][Full Text] [Related]
24. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients.
van der Hoek J; van der Lelij AJ; Feelders RA; de Herder WW; Uitterlinden P; Poon KW; Boerlin V; Lewis I; Krahnke T; Hofland LJ; Lamberts SW
Clin Endocrinol (Oxf); 2005 Aug; 63(2):176-84. PubMed ID: 16060911
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers.
Lin CC; Philips L; Xu C; Yeh LT
J Clin Pharmacol; 2004 Mar; 44(3):265-75. PubMed ID: 14973309
[TBL] [Abstract][Full Text] [Related]
26. Effect of food on the pharmacokinetics and pharmacodynamics of an oral ghrelin agonist (ARD-07) in healthy subjects.
MacLean CM; Casanova AT; Baselgia-Jeker L; Neave N; Larsen F; Skillern L; Drewe J; Beglinger C
J Clin Pharmacol; 2009 May; 49(5):553-9. PubMed ID: 19293342
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and systemic endocrine effects of the phyto-oestrogen 8-prenylnaringenin after single oral doses to postmenopausal women.
Rad M; Hümpel M; Schaefer O; Schoemaker RC; Schleuning WD; Cohen AF; Burggraaf J
Br J Clin Pharmacol; 2006 Sep; 62(3):288-96. PubMed ID: 16934044
[TBL] [Abstract][Full Text] [Related]
28. CDP-choline increases plasma ACTH and potentiates the stimulated release of GH, TSH and LH: the cholinergic involvement.
Cavun S; Savci V
Fundam Clin Pharmacol; 2004 Oct; 18(5):513-23. PubMed ID: 15482372
[TBL] [Abstract][Full Text] [Related]
29. The effects of recombinant human growth hormone (rhGH) supplementation on adipokines and C-reactive protein in obese subjects.
Albert SG; Haas MJ; Mooradian AD
Growth Horm IGF Res; 2007 Feb; 17(1):19-25. PubMed ID: 17118687
[TBL] [Abstract][Full Text] [Related]
30. A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate.
Zdravkovic M; Olsen AK; Christiansen T; Schulz R; Taub ME; Thomsen MS; Rasmussen MH; Ilondo MM
Eur J Clin Pharmacol; 2003 Feb; 58(10):683-8. PubMed ID: 12610745
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological characterisation of a new oral GH secretagogue, NN703.
Hansen BS; Raun K; Nielsen KK; Johansen PB; Hansen TK; Peschke B; Lau J; Andersen PH; Ankersen M
Eur J Endocrinol; 1999 Aug; 141(2):180-9. PubMed ID: 10427162
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic and pharmacodynamic modeling of NN703, a growth hormone secretagogue, after a single po dose to human volunteers.
Agersø H; Ynddal L; Søgaard B; Zdravkovic M
J Clin Pharmacol; 2001 Feb; 41(2):163-9. PubMed ID: 11210396
[TBL] [Abstract][Full Text] [Related]
33. Daily low-dose administration of growth hormone secretagogue stimulates pulsatile growth hormone secretion and elevates plasma insulin-like growth factor-1 levels in pigs.
Malmlöf K; Bauer MK; Johansen PB; Ankersen M; Veldhuis JD
Endocrine; 2001 Dec; 16(3):195-9. PubMed ID: 11954663
[TBL] [Abstract][Full Text] [Related]
34. Endocrinological effects of high-dose Hypericum perforatum extract WS 5570 in healthy subjects.
Schüle C; Baghai T; Sauer N; Laakmann G
Neuropsychobiology; 2004; 49(2):58-63. PubMed ID: 14981335
[TBL] [Abstract][Full Text] [Related]
35. Inhaled growth hormone (GH) compared with subcutaneous GH in children with GH deficiency: pharmacokinetics, pharmacodynamics, and safety.
Walvoord EC; de la Peña A; Park S; Silverman B; Cuttler L; Rose SR; Cutler G; Drop S; Chipman JJ
J Clin Endocrinol Metab; 2009 Jun; 94(6):2052-9. PubMed ID: 19336514
[TBL] [Abstract][Full Text] [Related]
36. Acute antagonism of dopamine D2-like receptors by amisulpride: effects on hormone secretion in healthy volunteers.
Wetzel H; Wiesner J; Hiemke C; Benkert O
J Psychiatr Res; 1994; 28(5):461-73. PubMed ID: 7897617
[TBL] [Abstract][Full Text] [Related]
37. Endocrinological effects of mirtazapine in healthy volunteers.
Schüle C; Baghai T; Bidlingmaier M; Strasburger C; Laakmann G
Prog Neuropsychopharmacol Biol Psychiatry; 2002 Dec; 26(7-8):1253-61. PubMed ID: 12502011
[TBL] [Abstract][Full Text] [Related]
38. Effect of growth hormone administration on circulating levels of luteinizing hormone, follicle stimulating hormone and testosterone in normal healthy men.
Ovesen P; Møller J; Jørgensen JO; Møller N; Christiansen JS
Hum Reprod; 1993 Nov; 8(11):1869-72. PubMed ID: 8288753
[TBL] [Abstract][Full Text] [Related]
39. Binding of THS by normal and TSI-containing globulins.
Bíró J
Endocrinol Exp; 1980 Mar; 14(1):9-16. PubMed ID: 6249567
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-1 Antagonism Decreases Cortisol Levels in Obese Individuals.
Urwyler SA; Schuetz P; Ebrahimi F; Donath MY; Christ-Crain M
J Clin Endocrinol Metab; 2017 May; 102(5):1712-1718. PubMed ID: 28324042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
